胰腺癌的靶向治疗

不能手术切除的或转移的胰腺癌预后不良,细胞毒药物治疗很少奏效,即使第一线化疗药物吉西他滨也只有中等度生存期益处,联合不同的细胞毒药物并不能明显改善,因此,继续寻找更有效的分子靶向药物和联合应用不同的治疗方法势在必行.埃洛替尼是一种口服、小分子表皮生长因子受体酪氨酸激酶抑制剂,在靶向药物中第一个被批准联合吉西他滨治疗晚期胰腺癌患者.吉西他滨联合其他靶向药物,包括单克隆抗体西妥昔单抗或贝伐单抗也被广泛研究,但迄今很少突出成就.进一步研究应继续探究胰腺癌发生的机制,识别相关的关键分子靶以利治疗.

Targeted therapy of pancreatic cancer

Unresectable or metastatic pancreatic cancer carries a poor prognosis,and systemic therapy with cytotoxic agents provides marginal benefit. Even the first-line chemotherapeutic agent, gemcitabine(GEM) has a modest survival benefit,and objective tumor response is rarely achieved. Combination of various cytotoxics did not produce a significant improvement either. For that reason,continuous search for better molecules targeted agents and/or combinations is inevitable. Erlotinib, an orally bioavailable small molecule inhibitor of the epidermal growth factor receptor tyrosine kinase, is the first of these targeted which compounds to be approved for use in combination with gemcimbine for patients with advanced pancreatic cancer. GEM with other targeted agents,including monoclonal antibodies: cetuximab or bevacizumab,also has been extensively evaluated,with limited success to date. Future research should continue to unravel the mechanism of pancreatic carcinogenesis and to identify key relevant molecular targets for therapeutic intervention.